Novartis Shares Del-Zota Regulatory Update: FDA Accepts BLA for Priority Review
Novartis announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the Biologics License Application (BLA) of del-zota (delpacibart zotadirsen) is sufficiently complete to permit a substantive review. According to…Learn More
